

PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of HUTCHINS et al.

Serial No.: 10/038,694

Art Unit: 1623

Filing Date: December 31, 2001

Examiner: Unknown

For:

Superficial Zone Protein and

Methods of Making and Using Same

RECEIVED

TECH CENTER 1600/2900

BOX DD

Commissioner for Patents Washington, D.C. 20231

Date: 12 February 2003

SUPPLEMENTALINFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	ij	Copies of the references are enclosed Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d)) A copy of the International Search Report which issued on International Application No PCT/US01/50379 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449, with the exception of those publications that have been previously cited in this case.
Α.	[]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	OR	·
	[]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.
Uni	ited S	CERTIFICATE OF MAILING (37 CFR 1.8) certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the tates Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed DD, Commissioner for Patents, Washington, D.C. 20231.

[X] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an [] Information Disclosure Statement under § 1.97(c) (\$180.00). C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No. In accordance with the requirements of 37 CFR 1.97(d): [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii). [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith. [X] Please charge any required fees to Deposit Account No.07-1392. [] A duplicate copy of this paper is attached.

Respectfully Submitted,

Attorney of Record: Michael M. Conger

Registration No. 43,562

Date: 12 February 2003
GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-2474 Facsimile: (919) 483-7988

FORM PTO	_1440-			7	ATTORNEY DOC	KET NO.	CERTAL		
INFORMAT	TON I	FSCY OF SURE ST	ATEMENT		PU4112US2	KEI NO.	SERIAL NO.		
	7	STORE ST	AICIVICIVI		APPLICANT		10/038,694		
f **		a coma est			HUTCHINS et al.				
	LEB S	o mas o			FILING DATE	CDOUD			
\	-				December 31, 2001		GROUP 1623		
	4/		IIS P	ATENT D	OCUMENTS		1023		
	100	* TRATE	1 0.5.1	ATENT D	OCUMENTS	- r	 	Filing Date	
Examiner		Patent	Issue Date	Name		Class	Subclass	If	
Initials		Number	13320 2410		1 tunic	Ciass	Subciass	Appropriate	
			l l						
							TEIVED		
			<u> </u>		· · · · · · · · · · · · · · · · · · ·				
						_			
_						FEB	2 4 2003		
					······································	-TECH-CF	NTER 1600/29)00 	
				<u> </u>		1.2011 05	11 F11 10001		
				ontinue on p					
		· -		N PATENT	DOCUMENTS				
		Document	Publication		~ .			Translation Yes No	
		Number	Date		Country	Class	Subclass	165 140	
						<u> </u>			
				. <u>-</u>					
<u>-</u>		y .							
						ļ			
				ontinue on p					
					Title, Journal-Date,				
	1.				mones can induce full			ypertrophy	
		leading to matrix	calcification," Jo	urnal of Bo	ne and Mineral Resea	rch 11(1):10:	5-113 (1996).		
	2. /	/ Ikegawa et al., "Isolation, characterization and mapping of the mouse and human PRG4 (proteoglycan 4)							
		genes," Cytogene							
	3. 7				al zone protein (SZP)				
					vial fibroblasts and art		ocytes localized	l to	
	chromosome 1q25," Journal of Ortopaedic Research 19(4):677-687 (Jun. 2001).								
	4. Robbins et al., "Immortalized human adult articular chondrocytes maintain cartilage-specific phenotype								
					neumatism 43(10):218				
	5. Theiler et al., "Clinical, biochemical and imaging methods of assessing osteoarthritis and clinical trials with								
		agents claiming 'c	chondromodulati	ng' activity,	" Osteoarthritis and C	Cartilage 2(1)	:1-23 (Mar. 199	4).	
							-		
					<u></u>				
	·		· · · · · · · · · · · · · · · · · · ·						
Market Same			C	ontinue on	page				
EXAMINER						DATECO	NSIDERED		
						1			
EXAMINER	Initia	l if citation conside	ered, whether or r	ot citation i	s in conformance with	MPEP 8 609	9: Draw line thre	nugh	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.